Daniel E. Fürst

34.4k total citations · 6 hit papers
258 papers, 22.1k citations indexed

About

Daniel E. Fürst is a scholar working on Rheumatology, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Daniel E. Fürst has authored 258 papers receiving a total of 22.1k indexed citations (citations by other indexed papers that have themselves been cited), including 147 papers in Rheumatology, 94 papers in Pathology and Forensic Medicine and 46 papers in Hematology. Recurrent topics in Daniel E. Fürst's work include Rheumatoid Arthritis Research and Therapies (133 papers), Systemic Sclerosis and Related Diseases (69 papers) and Systemic Lupus Erythematosus Research (54 papers). Daniel E. Fürst is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (133 papers), Systemic Sclerosis and Related Diseases (69 papers) and Systemic Lupus Erythematosus Research (54 papers). Daniel E. Fürst collaborates with scholars based in United States, United Kingdom and Italy. Daniel E. Fürst's co-authors include Michael H. Weisman, Ravinder N. Maini, Peter E. Lipsky, Paul Emery, E. William St. Clair, Joachim R. Kalden, Gregory R. Harriman, Ferdinand C. Breedveld, Marc Feldmann and Josef S Smolen and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Daniel E. Fürst

254 papers receiving 21.2k citations

Hit Papers

Infliximab and Methotrexate in the Treatment of Rheumatoi... 1993 2026 2004 2015 2000 1995 1999 1993 2010 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
    2000 2.4k citations Daniel E. Fürst et al. profile →
  2. American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
    1995 2.2k citations Maarten Boers, Daniel E. Fürst et al. Arthritis & Rheumatism profile →
  3. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
    1999 1.9k citations Daniel E. Fürst et al. profile →
  4. The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
    1993 1.3k citations Maarten Boers, Daniel E. Fürst et al. Arthritis & Rheumatism profile →
  5. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis
    2010 516 citations Veena K. Ranganath, Daniel E. Fürst et al. profile →
  6. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
    2005 502 citations Arthur Kavanaugh, Gerd R Burmester et al. Arthritis & Rheumatism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel E. Fürst United States 64 12.3k 5.3k 5.0k 4.6k 2.6k 258 22.1k
Michael H. Weisman United States 67 14.9k 1.2× 5.0k 1.0× 2.4k 0.5× 6.2k 1.3× 1.9k 0.7× 340 22.2k
Larry W. Moreland United States 59 12.2k 1.0× 5.0k 1.0× 2.3k 0.5× 4.7k 1.0× 2.4k 0.9× 291 18.9k
Edward Keystone Canada 69 17.0k 1.4× 7.8k 1.5× 3.1k 0.6× 6.8k 1.5× 4.2k 1.6× 404 24.5k
Ben A. C. Dijkmans Netherlands 83 18.3k 1.5× 6.1k 1.2× 2.3k 0.5× 6.3k 1.4× 2.1k 0.8× 332 25.0k
Pier Luigi Meroni Italy 81 18.0k 1.5× 7.6k 1.4× 3.0k 0.6× 9.0k 1.9× 1.0k 0.4× 621 28.6k
Joel M. Kremer United States 77 15.2k 1.2× 6.9k 1.3× 2.3k 0.5× 5.0k 1.1× 4.1k 1.5× 322 23.2k
Vibeke Strand United States 73 15.4k 1.3× 5.6k 1.1× 2.6k 0.5× 6.3k 1.4× 2.0k 0.8× 522 22.9k
Yoshiya Tanaka Japan 80 14.5k 1.2× 5.2k 1.0× 2.8k 0.6× 9.6k 2.1× 3.8k 1.4× 1.1k 30.4k
Daniel E. Furst United States 73 6.1k 0.5× 2.3k 0.4× 6.9k 1.4× 3.8k 0.8× 1.5k 0.6× 382 17.5k
Frank C. Arnett United States 67 24.3k 2.0× 5.6k 1.1× 7.2k 1.4× 9.2k 2.0× 2.3k 0.9× 196 37.7k

Countries citing papers authored by Daniel E. Fürst

Since Specialization
Citations

This map shows the geographic impact of Daniel E. Fürst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel E. Fürst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel E. Fürst more than expected).

Fields of papers citing papers by Daniel E. Fürst

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel E. Fürst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel E. Fürst. The network helps show where Daniel E. Fürst may publish in the future.

Co-authorship network of co-authors of Daniel E. Fürst

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel E. Fürst. A scholar is included among the top collaborators of Daniel E. Fürst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel E. Fürst. Daniel E. Fürst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Charles‐Schoeman, Christina, Jon T. Giles, Nancy E. Lane, et al.. (2024). Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years. Rheumatology and Therapy. 11(1). 157–175. 5 indexed citations
2.
Fleischmann, Roy, et al.. (2022). Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis. Rheumatology and Therapy. 9(2). 649–661. 1 indexed citations
3.
Barroso, Nashla, et al.. (2019). SAT0698-HPR SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS OF INFECTION TYPES AND THE EFFECT OF MEDICATIONS ON INFECTION IN SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases. 78. 1451–1452. 1 indexed citations
4.
Klokker, Louise, Thasia Woodworth, Kathleen M. Andersen, et al.. (2019). Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. The Journal of Rheumatology. 46(9). 1173–1178. 6 indexed citations
5.
Bruni, Cosimo, Francesca Braschi, Yossra A. Suliman, et al.. (2018). Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis. The Journal of Rheumatology. 46(6). 603–608. 12 indexed citations
6.
Gordon, Kenneth B., Craig L. Leonardi, Daniel E. Fürst, et al.. (2017). Highlights of Skin Disease Education Foundation’s 41st Annual Hawaii Dermatology SeminarTM. Seminars in Cutaneous Medicine and Surgery. 36(3S). S52–S59. 1 indexed citations
7.
Fürst, Daniel E., Jonathan Kay, Mary Chester Wasko, et al.. (2013). The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Lara D. Veeken. 52(10). 1845–1855. 26 indexed citations
8.
9.
Fürst, Daniel E., et al.. (2011). Double-Blind, Randomized, Controlled, Pilot Study Comparing Classic Ayurvedic Medicine, Methotrexate, and Their Combination in Rheumatoid Arthritis. JCR Journal of Clinical Rheumatology. 17(4). 185–192. 53 indexed citations
10.
11.
Fürst, Daniel E.. (2009). Certolizumab pegol—what role does this new TNF inhibitor have in the treatment of RA?. Nature Reviews Rheumatology. 5(3). 134–135. 5 indexed citations
12.
Fürst, Daniel E.. (2008). Outcome measures in rheumatologic clinical trials and systemic sclerosis. Lara D. Veeken. 47(Supplement 5). v29–v30. 23 indexed citations
13.
14.
Ranganath, Veena K. & Daniel E. Fürst. (2007). Disease-Modifying Antirheumatic Drug Use in the Elderly Rheumatoid Arthritis Patient. Rheumatic Disease Clinics of North America. 33(1). 197–217. 30 indexed citations
15.
Seibold, James R., Joseph H. Korn, Robert W. Simms, et al.. (2000). Recombinant Human Relaxin in the Treatment of Scleroderma. Annals of Internal Medicine. 44 indexed citations
16.
Maloney, Sean, Anajane G. Smith, Daniel E. Fürst, et al.. (1999). Microchimerism of maternal origin persists into adult life. Journal of Clinical Investigation. 104(1). 41–47. 355 indexed citations
17.
Gardner, Gregory C. & Daniel E. Fürst. (1995). Disease-Modifying Antirheumatic Drugs. Drugs & Aging. 7(6). 420–437. 25 indexed citations
18.
Fürst, Daniel E.. (1994). PREDICTORS OF WORSENING CLINICAL VARIABLES AND OUTCOMES IN RHEUMATOID ARTHRITIS. Rheumatic Disease Clinics of North America. 20(2). 309–319. 12 indexed citations
19.
Hirschberg, Joel, et al.. (1987). Esophagitis in scleroderma. Gastroenterology. 92(2). 421–428. 22 indexed citations
20.
Lewis, Alan J. & Daniel E. Fürst. (1987). Nonsteroidal anti-inflammatory drugs : mechanisms and clinical use. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael H. Weisman Breakdown of academic impact, for papers by Larry W. Moreland Breakdown of academic impact, for papers by Edward Keystone Breakdown of academic impact, for papers by Ben A. C. Dijkmans Breakdown of academic impact, for papers by Pier Luigi Meroni Breakdown of academic impact, for papers by Joel M. Kremer Breakdown of academic impact, for papers by Vibeke Strand Breakdown of academic impact, for papers by Yoshiya Tanaka Breakdown of academic impact, for papers by Daniel E. Furst Breakdown of academic impact, for papers by Frank C. Arnett
Rankless by CCL
2026